Affiliations of authors: S. Guruswamy, D. M. Benbrook (Departments of Obstetrics and Gynecology and Biochemistry and Molecular Biology), S. Lightfoot (Department of Pathology), M. A. Gold, R. T. Ivey (Department of Obstetrics and Gynecology), R. Hassan (Department of Medicine), University of Oklahoma Health Sciences Center, Oklahoma City; K. D. Berlin, Department of Chemistry, Oklahoma State University, Stillwater.
Correspondence to: Doris M. Benbrook, Ph.D., Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, P.O. Box 26901, Rm. WP2470, Oklahoma City, OK 73190. (e-mail: Doris-Benbrook{at}ouhsc. edu).
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
A promising candidate drug for ovarian cancer chemoprevention is fenretinide, i.e., N-(4-hydroxyphenyl)retinamide (4-HPR), which belongs to a family of synthetic retinoic acid (RA) analogues called retinoids. Its promising clinical activity was observed in a randomized clinical trial conducted at the Istituto Nazionale Tumori in Italy. In this trial, women who had surgery for breast cancer were randomly assigned to receive 200 mg of 4-HPR per day or a placebo for 5 years to determine whether 4-HPR reduced the incidence of second primary tumors (5,6). A secondary finding of this trial was that statistically significantly fewer ovarian cancers developed in women who received 4-HPR. This result, which suggests that 4-HPR may reduce the risk of ovarian cancer, has led to several clinical trials to evaluate its efficacy as a chemoprevention agent.
Retinoids are considered to be one of the most promising classes of cancer chemoprevention agents by the Chemoprevention Working Group to the American Association for Cancer Research (7). These drugs elicit biologic effects by regulating gene transcription via a series of nuclear receptors, which are ligand-inducible transcription factors that belong to the steroid receptor superfamily (8,9). There are two classes of retinoid receptors known as RA receptors (RARs) and retinoid X receptors (RXRs), each with three distinct subtypes (,
, and
). The RARs bind to DNA as homodimers with self or as heterodimers with other nuclear receptors. The retinoid receptors function only as heterodimers with RXRs, while RXRs function both as homodimers and as heterodimers with RARs (810), the thyroid hormone receptors (8), the vitamin D receptor (8), the peroxisome proliferator-activated receptor (11), and several orphan receptors (1214). The retinoid receptor dimers regulate gene expression by binding to specific DNA sequence elements found in retinoid-responsive gene promoters termed RA-responsive elements (RAREs) (8,9,15).
The 4-HPR compound is similar to the classic retinoids in that it can induce transactivation of RAREs in intact cells (16). Since 4-HPR does not directly bind to retinoid receptors, this transactivation may be due to 4-HPR's ability to inhibit RA catabolism, thus causing increased concentrations of intracellular RA (17). Another similarity between 4-HPR and classic retinoids is that both can induce F9 mouse teratocarcinoma cell differentiation in a receptor-dependent manner at 1 µM (18). At concentrations of 312.5 µM, however, 4-HPR differs from classic retinoids in that it induces apoptosis in a variety of cell lines (1824). The finding that 4-HPR can induce apoptosis in retinoid receptor null cells indicates that the molecular mechanism of apoptosis induction is independent of retinoid receptor activation (18). Other promising novel retinoids, such as CD437 (25,26), and some of the retinoid class, called heteroarotinoids, also induce apoptosis (Liu S, Kamelle S, Guruswamy S, Dhar A, Klucik J, Brown C, et al.: manuscript in preparation). The classic retinoids, on the other hand, are poor inducers of apoptosis as single agents, although they can enhance apoptosis when combined with DNA-damaging agents (20,26,27). Therefore, retinoids that can induce apoptosis through receptor-independent mechanisms may have very different biologic effects depending on the physiologic concentrations achieved in clinical trials [(26); Liu S, Kamelle S, Guruswamy S, Dhar A, Klucik J, Brown C, et al.: manuscript in preparation]. Since concentrations of retinoids greater than 1 µM are difficult to achieve physiologically, it is most likely that apoptotic retinoids will act similarly to classic retinoids in clinical trials (28). In the trial conducted by Istituto Nazionale Tumori, the plasma concentration of 4-HPR achieved in treated women ranged from 340 to 868 nM (29). Therefore, the concentrations in the ovarian tissue of treated women were not likely to have reached the levels required for apoptosis, and we hypothesize that induction of differentiation in ovarian cancer cells contributed to the chemoprevention observed.
The objective of this study was to compare the effects of clinically achievable concentrations of apoptotic retinoids and classic growth-inhibitory retinoids on growth, differentiation, and apoptosis in ovarian tissue. To evaluate therapeutic effects, we developed an organotypic culture model of ovarian tumors by growing established cell lines and primary cultures inside collagen gels. The retinoids used in this study include a series of compounds belonging to a class of synthetic retinoids called heteroarotinoids that consist of aromatic structures (arotinoids) containing heteroatoms in a ring. The presence of the heteroatom has been shown to decrease the toxicity of arotinoids (30). Heteroarotinoids with similar biologic activity profiles to 9-cis-RA, but with various receptor specificities, were compared with heteroarotinoids with similar profiles to 4-HPR and receptor-independent induction of apoptosis [Liu S, Kamelle S, Guruswamy S, Dhar A, Klucik J, Brown C, et al.: manuscript in preparation; (3034)]. It was hypothesized that retinoids would increase the expression of mucins, which are markers of ovarian epithelial differentiation, and specifically increase the MUC1 mucin, which is a marker of glandular differentiation (35,36).
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Retinoids.
Structures of arotinoids and heteroarotinoids used in these experiments are given in Fig. 1; their biologic characteristics are described in Table 2
. The arotinoid and heteroarotinoids in the laboratory of K. D. Berlin at Oklahoma State University, Stillwater, and were synthesized and their receptor specificity was determined as described previously [Nhet90 and NHet17 are compounds 2 and 3, respectively (32), OHet72, SHet50, OHet26, and Arot21 are compounds 6, 16, 8, and 11, respectively (31), and SHetA2, SHetA3, and SHetA4 are compounds 11, 12, and 13, respectively (34)]. The 4-HPR compound was a gift from R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ, and 9-cis-RA was obtained from a commercial source (Bio-Mol, Plymouth Meeting, PA). All retinoids were dissolved in dimethyl sulfoxide (DMSO) and stored as aliquots of 1000x stocks at -70 °C. Since the retinoids are sensitive to light, all manipulations involving retinoids were performed under subdued lighting. Each experiment included control cultures that received the same volume of DMSO solvent that was administered in the retinoid treatment. The concentration of DMSO in each experiment was always less than or equal to 0.01%, which is not toxic and does not induce differentiation.
|
|
Organotypic cultures. Single-cell suspensions of the ovarian carcinoma cell lines and the primary ovarian cultures, at passage 2, were quantitated with a particle counter. Volumes containing 105 ovarian cells and 105 3T3 fibroblasts were mixed and centrifuged. The cell pellet was resuspended in a 4 °C solution containing complete MEM and rat tail collagen I (Collaborative Biomedical Products, Bedford, MA), a solution that is liquid at 4 °C. The suspension was poured into Falcon cell culture inserts with transparent membranes containing 0.4-µm pores (Becton Dickinson, Franklin Lakes, NJ) that were placed in tissue culture plates. After the collagen was allowed to solidify at 37 °C, a layer of 3 x 105 ovarian cells without fibroblasts was placed on top of the collagen gels. The liquid on top of the gel was allowed to evaporate, and the medium surrounding the insert was replenished every 2 days. Retinoid treatment was initiated after 1 week of growth and replenished with each medium change. Retinoids were administered by mixing liquid drug stocks into the medium surrounding the insert. Untreated control cultures were treated with the same volume of DMSO administered in retinoid treatments. After 2 weeks of retinoid treatment, the cultures were cut in half. One half was fixed in formalin and subsequently embedded in paraffin and sectioned, and the other half was snap-frozen in liquid nitrogen. The experiment was repeated two to five times for each cell line.
Histochemical and immunohistochemical analyses. Sections from the paraffin-embedded blocks were stained with hematoxylineosin (H & E) for histologic evaluation. Mucin expression was detected by staining with the periodic acidSchiff (PAS) stain kit (American Master* Tech Scientific, Inc., Lodi, CA), and apoptosis was detected via the TUNEL assay (i.e., terminal deoxynucleodidyl transferase-mediated biotin-deoxyuridine triphosphate nick-end labeling) by staining with the Klenow-FragELTM DNA Fragmentation Kit (Oncogene Research Products, Cambridge, MA) according to the manufacturer's instructions. A Ki-67 Kit (Zymed Laboratories Inc., South San Francisco, CA) was used to stain 5-µm sections of paraffin-embedded organotypic culture blocks according to the manufacturer's instructions. The slides were counterstained with Mayer's hematoxylin. Immunohistochemical staining for MUC1 was performed on 5-µm sections that were deparaffinized and subjected to antigen retrieval. The slides were incubated with diluted MUC1 antibody (1 : 75; Novocastra Laboratories Ltd., New Castle, U.K.) for 1 hour and subsequently washed with phosphate-buffered saline two times. The HistostainPlus Kit (Zymed Laboratories, Inc.) was used for the secondary antibody and color development. A biotinylated second antibody was added and incubated for 20 minutes. This was followed by adding avidinperoxidase complex for 30 minutes and the enzyme substrate aminoethyl carbozole for 7 minutes. Finally, the slides were counterstained with Mayer's hematoxylin for 1 minute, rinsed in 1% ammonia solution, and mounted in crystal mount.
Pathology review. All stained slides were labeled with a secret code and reviewed in a blinded manner by an experienced pathologist (S. Lightfoot), who did not know the meaning of the code. The following characteristic features in H & E-stained sections were used to identify apoptotic cells: nuclei that were shrunken and markedly hyperchromatic, multiple small pieces of nuclear material in the cell, cell cytoplasm that contained some fragment of a nucleus, and cell cytoplasm that resided as a small dense segment without nuclear material. In a separate assay, the TUNEL-stained slides were screened at 10x magnification, and then the individual cells or cell pieces were examined at 40x magnification. Cells that had granular brown pigment in the nucleoplasm were scored as positive. Cells were scored as negative if no staining was present or if the brown pigment was smooth and nongranular.
Quantification of PAS and MUC1 staining. A scoring system was used that assigned each stained section a numeric value on the basis of the staining intensity and the percent of positive cells. The numeric values assigned on the basis of staining intensity were as follows: 1) slight staining outlining the cell wall, 2) moderate staining with some staining of the cell proper, and 3) moderate to heavy staining with marked cell staining. The numeric values assigned on the basis of the percent of positive cells were as follows: 1) 0%10%, 2) 10%50%, 3) 51%80%, and 4) greater than 80%. The score was then derived by multiplying the assigned category number of the staining intensity by the assigned category number of the percentage of positive cells.
Statistical analysis. All data were entered into Microsoft Excel 5.0. GraphPad Software was used to perform two-tailed t tests and correlation analysis for TUNEL and Ki-67 parametric results. For analysis involving the nonparametric PAS stain and MUC1 scores, the two-tailed MannWhitney U test and Spearman correlation analyses were performed. All P values of less than .05 were considered to be statistically significant.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
To evaluate the mechanism of retinoid action on ovarian cancer cells, a series of 11 retinoids were chosen on the basis of their in vitro growth-inhibition activity against OVCAR-3, Caov-3, and SK-OV-3 ovarian carcinoma cell lines. To classify the heteroarotinoids, a standard cytotoxicity assay was performed to differentiate between drugs that cause cell loss similar to 4-HPR and those that inhibit growth similar to 9-cis-RA. Since the doubling times of these cultures were approximately 48 hours and the cultures were treated for 72 hours (1.5 doubling times), a greater than 67% decrease in the number of cells would indicate that cell loss occurred. The three retinoids that exhibited a greater than 74% cell decrease, similar to 4-HPR, belong to a category of heteroarotinoids that are known to induce apoptosis and act through receptor-independent mechanisms (Fig. 1; Liu S, Kamelle S. Guruswamy S, Dhar A, Klucik J, Brown C, et al.: manuscript in preparation). The six retinoids that caused a less than 50% cell decrease similar to 9-cis-RA inhibit tumor cell growth and exhibited a wide range of RAR specificities [Fig. 1
; receptor-active retinoids (32,33)]. Two of the receptor-active retinoids were classified as apoptotic on the basis of their activities in further experimentation as described in the next sections.
Ovarian Organotypic Cultures
The objective of this study was to determine the effects of clinically achievable concentrations of these retinoids on ovarian tissue. Monolayer cultures of cells are not accurate representations of in vivo tissue because they lack the types of interactions that cells have with other cells and with the extracellular matrix in vivo. These interactions are known to influence gene expression and, thus, the constitution and behavior of cells. We have developed an ovarian organotypic model system that allows ovarian tissue growth inside as well as on top of a collagen gel (Fig. 2, A and B). The growth of tumor cells inside the collagen allows a representation of tumors that have invaded stromal tissue. In the presence of fibroblasts, established cell lines and primary cultures of ovarian cancer formed colonies inside the collagen, while normal ovarian epithelial cells remained as single cells inside the collagen. The primary ovarian carcinoma cultures did not consistently form colonies in the absence of added fibroblasts. Fibroblasts were, therefore, included in all experiments to standardize the procedure.
|
|
Retinoid treatment also reversed the cancerous phenotype of the O2 primary serous papillary cultures but did not induce glandular formation (Fig. 2, I and J).
Apoptosis
Microscopic evaluation of H & E-stained sections revealed that, in the absence of retinoids, apoptosis occurred predominantly in cells that were located at the periphery of the colonies. In the presence of retinoids, apoptosis was observed at both the center and at the periphery of the colonies. To quantitate retinoid effects on apoptosis, the TUNEL assay was performed and quantitated by blinded pathologic review (Fig. 2, K; Table 2
). The OVCAR-3 and Caov-3 control cultures exhibited 10% and 5% cells undergoing apoptosis, respectively. All of the retinoids that were categorized as apoptotic based on the monolayer cytotoxicity assays induced high percentages of cells undergoing apoptosis in the OVCAR-3 cultures. While five of the retinoids classified as growth inhibitory induced low to no increases in apoptosis, two of this class, 9-cis-RA and SHet50, induced levels equal to those of the apoptotic class of retinoids. Therefore, these two compounds were reclassified into the apoptotic group. The group of retinoids classified as apoptotic on the basis of the organotypic culture assay induced significantly higher levels of apoptotic cells than the growth-inhibitory retinoids (P<.0001; two-tailed t test). It was predicted that apoptosis would be observed inside the lumina of the glandular structures induced by retinoids, but this was not observed on microscopic evaluation of sections stained by the TUNEL assay. In general, it appeared that the colonies were either differentiating or undergoing apoptosis and that these two activities were not being induced simultaneously in the same colonies.
Ki-67/myb Expression
To determine if both classes of retinoids were capable of decreasing the growth fraction, the sections were immunohistochemically stained for Ki-67, which is considered to be a marker of proliferating cells (37). All of the retinoids decreased the percentage of Ki-67-positive cells (Table 2). There was no significant difference between the inhibition of Ki-67 induced by the apoptotic class of retinoids and the growth-inhibitory class of retinoids (P = .49; two-tailed t test). No statistically significant correlations were observed between the effects of the retinoids on the Ki-67 and the TUNEL assays (linear regression: r2 = .24 and P = .24 for apoptotic retinoids, r2 = .04 and P = .70 for growth-inhibitory retinoids, and r2 = .00 and P = .99 for all retinoids combined).
Mucin Expression
To determine whether mucin was being produced in these glands, sections of the organotypic cultures were stained with PAS. As can be seen in Fig. 2, L, positive PAS staining was observed in some cells and inside the glandular lumina. In the absence of retinoids, OVCAR-3 expressed high levels of mucin, with a score of 6 of 12; Caov-3 expressed a low level, with a score of 1 of 12; and neither SK-OV-3 nor the primary serous ovarian cancer culture O2 produced mucin. Both classes of retinoids increased PAS staining of mucin. The intensity and percentage of cells staining PAS positive were estimated semiquantitatively by pathology review and were used to generate a score as described in the "Materials and Methods" section (Table 2
). The levels of PAS staining in the cultures treated with the different classes of retinoids were not statistically significantly different (two-tailed MannWhitney U tests; P = .66 for both OVCAR-3 and Caov-3) and did not correlate with the results of the TUNEL or Ki-67 assays as separate groups or as a single group (Spearman correlations: PAS and TUNELr = .31 and P = .50 for the apoptotic retinoids, r = .56 and P = .24 for the growth-inhibitory retinoids, and r = .15 and P = .65 for all retinoids combined; PAS and Ki67r = .26 and P = .60 for apoptotic retinoids, r = .15 and P = .80 for growth-inhibitory retinoids, and r = .23 and P = .47 for all retinoids combined).
MUC1 Expression
To evaluate the role of the MUC1 mucin protein in the mechanism of retinoid action, MUC1 expression was evaluated in treated and untreated OVCAR-3 cultures by immunohistochemistry. Clumps of cells in the untreated cultures exhibited low to undetectable levels of MUC1 protein, with a score of 1 of 12 (Fig. 3, A). In contrast, MUC1 was highly expressed on the luminal surface of cells in the glandular structures that developed in retinoid-treated cultures (Fig. 3, B and C
). Scoring of the intensity and percent positive cells revealed that all of the retinoids increased MUC1 expression. The greater induction of MUC1 by the growth-inhibitory retinoids in comparison to the apoptotic retinoids approached statistical significance (Table 2
; two-tailed MannWhitney U test; P = .05). The effects of retinoids on the PAS scores and the MUC1 scores did not correlate, suggesting that additional MUCs are involved in the mechanism of retinoid induction of PAS staining (Spearman correlation: P = .84 for apoptotic retinoids, P = .80 for growth-inhibitory retinoids, and P = .64 for all retinoids combined). Grouping all of the retinoids together did not demonstrate a correlation between MUC1 staining and TUNEL, PAS, or Ki-67 (two-tailed Spearman correlation: r = -.14 and P = .67 for TUNEL, r = -.15 and P = .64 for PAS, and r = -.53 and P = .08 for Ki-67). Of interest, when the two classes of retinoids were evaluated separately, the effects of the growth-inhibitory retinoids exhibited a statistically significant correlation between increased MUC1 expression and decreased Ki-67 but not between MUC1 induction and the TUNEL assay (two-tailed Spearman correlation: r = -.93 and P = .02 for MUC1 and Ki-67 and r = .20 and P = .71 for MUC1 and TUNEL). In contrast, the apoptotic retinoids exhibited a statistically significant correlation between an increase in MUC1 and the TUNEL assay but not between MUC1 and Ki-67 (two-tailed Spearman correlation: r = .83 and P = .03 for MUC1 and TUNEL and r = -.49 and P = .27 for MUC1 and Ki-67).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
These results stimulate questions regarding the role of differentiation and mucin expression in ovarian tumorigenesis and the potential of the retinoid differentiation-inducing activities to effectively prevent ovarian tumorigenesis and metastases. Epithelial mucins are a family of glycoproteins characterized by pleomorphic tandem repeat peptide sequences and O-linked carbohydrate side chains. Increased production of aberrantly glycosylated mucins has been observed in both malignant and low-malignant potential ovarian tissues as well as in many adenocarcinomas, including those in the breast, pancreas, lung, and colon (4043). Although there have been no studies of the regulation of mucin expression by retinoids in the ovary, there have been reports of such regulation in other organ sites. Vitamin A and its natural metabolite, RA, are required for the normal growth and differentiation of epithelium. During vitamin A deprivation, the normal mucosecretory differentiation of trachea undergoes metaplasia to a squamous type of differentiation, and the normal vaginal and cervical squamous differentiation undergoes metaplasia to a columnar type of differentiation (44). Decreased expression of mucin genes has been observed during vitamin A-induced squamous metaplasia of tracheobronchial epithelium (45). Synthetic retinoids and RA can restore normal differentiation in these tissues in association with restoration of the normal expression pattern of mucin genes (45,46).
There is substantial evidence implicating MUC1 in the metastatic process. MUC1 is the best characterized mucin protein and is expressed on the apical surface of most normal glandular cells. The pattern of MUC1 expression and glycosylation in tumor tissue has been found to differ substantially from that found in normal tissue. Since the architecture of tumor tissue is usually disrupted, MUC1 is often expressed in an unorganized fashion throughout the cell surfaces in tumors, in contrast to the polarized expression limited to the apical surface of normal glands (47). In addition, the MUC1 proteins found on tumor cells are underglycosylated, with fewer and less complex carbohydrate side chains (48). The increased expression of aberrantly glycosylated MUC1 has been implicated in increasing metastatic potential (4951).
In this study, the induction of MUC1 expression suggests caution with regard to using retinoids in the treatment of advanced disease with metastatic potential. The induction of MUC1 expression in this study was associated with the strongest staining at the surface of glandular lumina, which is the pattern of expression in normal tissue. In contrast, increased MUC1 expression observed in tumors occurs in an unorganized pattern with expression on all of the cell surfaces (47). Therefore, retinoid induction of glandular patterns of MUC1 expression may not increase metastasis, as has been suggested for the deregulated patterns of MUC1 expression observed in tumors. Retinoids offer substantial promise as chemopreventative agents, with the potential to act earlier than the metastatic phase of tumorigenic progression. The role of MUC1 in growth inhibition is supported by the statistically significant correlation between MUC1 induction and decreased Ki-67 expression after treatment with the growth-inhibitory retinoids; this role is clouded, however, by the lack of correlation of these two parameters by the apoptotic retinoids. Perhaps the final measurement of MUC1 over time in apoptotic retinoid-treated cultures is reduced relative to growth-inhibitory retinoid-treated cultures by loss of the most responsive cells because of apoptosis, which is suggested by the greater induction of MUC1 by the growth-inhibitory retinoids in comparison to the apoptotic retinoids.
The role of MUC1 in both growth inhibition and apoptosis suggests that these two activities share a common upstream pathway that branches off after MUC1 induction. The similar levels of Ki-67 repression by both classes of retinoids support this suggestion and are consistent with the observation that apoptotic retinoids can act similarly to classic retinoids at low concentrations. The simultaneous induction of MUC1 and inhibition of Ki-67 by retinoids in this study are consistent with the inverse relationship between growth and differentiation. While both classes of retinoids share these activities, the apoptotic retinoids appear to have additional functions that result in apoptosis. The correlation of MUC1 and apoptosis induction by the apoptotic retinoids may be a consequence of the potencies of individual retinoids and may not be due to a direct role of MUC1 in the mechanism of retinoid-induced apoptosis. Future studies are planned to test if MUC1 and other mucin genes are mediators or consequences of ovarian tumorigenesis and retinoid action.
The role of RXRs in the mechanism of retinoid action was tested with compound OHet72, a rexinoid that is specific for RXRs (31). Substantial inhibition of Ki-67 staining and induction of PAS staining in OHet72-treated cultures indicate that RXR activation is sufficient for the decrease in growth fraction and induction of differentiation. This result does not rule out a role for RARs in these activities, however, because the complex interplay of these receptors as heterodimers suggests that some of the biologic activities of these receptors may be redundant. The potent induction of differentiation by the apoptotic group of retinoids could be due to indirect activation of RARs as is known to occur with 4-HPR (16). The lack of induction of apoptosis by the rexinoid OHet72 suggests that RXR activation is not sufficient to induce this activity. However, although receptor-specific compounds can be used to rule out the requirement of nonactivated receptors in indirect biologic activities, their structural limitations may prevent sufficient potency on the activated receptors to induce the indirect biologic activity. Therefore, although the structure of OHet72 confers specificity for RXRs, it may not induce sufficient potency for induction of apoptosis.
Comparison of the heteroarotinoid structures with their biologic activities revealed that the compounds containing ester linkages were unable to induce apoptosis. The ester linkage is more freely rotating than the corresponding linkages of the apoptotic heteroarotinoids (30). The apoptotic retinoids appear to hold greater promise as chemoprevention agents, since they induce similar levels of growth inhibition and differentiation induction as the growth-inhibitory retinoids, while inducing statistically significant greater levels of apoptosis. The observation that clumps of OVCAR-3 cells inside the collagen were undergoing either differentiation or apoptosis is consistent with the heterogeneous population of cells in this cell line. The clumps arise from single cells that have a variety of abnormalities. Our results suggest that retinoids will induce differentiation in cells that have retained differentiating potential and yet do not differentiate unless an appropriate stimulus is received. On the other hand, if the cell has lost differentiation potential, retinoids will induce the cell into the pathway of a natural form of cell death, apoptosis.
The SK-OV-3 cell line consists of a heterogeneous population of cells that exhibit resistance to retinoid treatment in monolayer culture (52,53). In this study, increased amounts of cytoplasm and more rounded nuclei were induced in SK-OV-3 organotypic cultures by retinoids. Despite these improvements in cellular morphology, no glandular structures were observed, suggesting that this cell line may be too dedifferentiated to respond to retinoids at a histologic level. It also exhibited undetectable levels of basal or induced apoptosis, which may be a result of the lack of p53 protein expression in this cell line. These results demonstrate that organotypic cultures can be used to evaluate retinoid activities, such as histologic changes and observation of glandular structures, that are not detectable in monolayer cultures. In addition, two of the retinoids that did not induce apoptosis in monolayer cultures, 9-cis-RA and SHet50, were capable of inducing apoptosis in organotypic cultures.
In conclusion, clinically achievable concentrations of retinoids reverse the cancerous phenotype, decrease the growth fraction, and induce MUC1 expression in ovarian organotypic cultures. A subset of retinoids exhibits the additional activity of apoptosis induction. MUC1 induction is implicated in the mechanisms of apoptosis and growth inhibition. These activities demonstrate substantial promise for the effectiveness of these compounds as ovarian cancer chemoprevention agents.
![]() |
NOTES |
---|
Presented in part at the 91st annual meeting of the American Association for Cancer Research, San Francisco, CA, April 15, 2000.
We thank Rebecca Bonner for teaching photomicrograph techniques.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1
Murphy GP. Cancer statistics, 2000. CA Cancer J Clin 2000;50:733.
2
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1997;334:16.
3 Boyd J, Rubin SC. Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol 1997:64:196206.[Medline]
4 Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997:277:9971003.[Abstract]
5 Veronesi U, De Palo G, Costa A, Formelli F, Marubini E, Del Vecchio M. Chemoprevention of breast cancer with retinoids. J Natl Cancer Inst Monogr 1992;12:937.[Medline]
6 De Palo G, Veronesi U, Camerini T, Formelli F, Mascotti G, Boni C, et al. Can fenretinide protect women against ovarian cancer? [letter]. J Natl Cancer Inst 1995;87:1467.[Medline]
7
Prevention of cancer in the next millennium. Report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res 1999;59:474358.
8 Giguere V. Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. Endocr Rev 1994;15:6179.[Medline]
9 Petkovich M. Regulation of gene expression by vitamin A: the role of nuclear retinoic acid receptors. Annu Rev Nutr 1992;12:43371.
10 Zhang XK, Lehmann J, Hoffman B, Dawson MI, Cameron J, Graupner G, et al. Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid. Nature 1992;358:58791.[Medline]
11
Palmer CN, Hsu MH, Muerhoff AS, Griffin KJ, Johnson EF. Interaction of the peroxisome proliferator-activated receptor alpha with the retinoid X receptor alpha unmasks a cryptic peroxisome proliferator response element that overlaps an ARP-1 binding site in the CYP4A6 promoter. J Biol Chem 1994;269:180839.
12 O'Malley B. The steroid receptor superfamily: more excitement predicted for the future. Mol Endocrinol 1990;4:3639.[Medline]
13 Kliewer SA, Umesono K, Heyman RA, Mangelsdorf DJ, Dyck JA, Evans RM. Retinoid X receptor-COUP-TF interactions modulate retinoic acid signaling. Proc Natl Acad Sci U S A 1992;89:144852.[Abstract]
14 Apfel R, Benbrook D, Lernhardt E, Ortiz MA, Salbert G, Pfahl M. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol Cell Biol 1994;14:702535.[Abstract]
15
de The H, Vivanco-Ruiz MM, Tiollais P, Stunnenberg H, Dejean A. Identification of a retinoic acid responsive element in the retinoic acid receptor gene. Nature 1990;343:17780.[Medline]
16
Fanjul AN, Delia D, Pierotti MA, Rideout D, Yu JQ, Pfahl M, et al. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996;271:224416.
17 Taimi M, Breitman TR. N-4-Hydroxyphenylretinamide enhances retinoic acid-induced differentiation and retinoylation of proteins in the human acute promyelocytic leukemia cell line, NB4, by a mechanism that may involve inhibition of retinoic acid catabolism. Biochem Biophys Res Commun 1997;232:4326.[Medline]
18
Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res 1999;59:148.
19 Hsieh TC, Ng C, Wu JM. The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) exerts antiproliferative and apoptosis-inducing effects in the androgen-independent human prostatic JCA-1 cells. Biochem Mol Biol Int 1995;37:499506.[Medline]
20 Oridate N, Lotan D, Xu XC, Hong WK, Lotan R. Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 1996;2:85563.[Abstract]
21 Pellegrini R, Mariotti A, Tagliabue E, Bressan R, Bunone G, Coradini D, et al. Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. Cell Growth Differ 1995,6:8639.[Abstract]
22 Eicher SA, Lotan R. Differential effects of retinoic acid and N-(4-hydroxyphenyl)retinamide on head and neck squamous cell carcinoma cells. Laryngoscope 1996;106(12 Pt 1):14715.[Medline]
23
Roberson KM, Penland SN, Padilla GM, Selvan RS, Kim CS, Fine RL, et al. Fenretinide: induction of apoptosis and endogenous transforming growth factor in PC-3 prostate cancer cells. Cell Growth Differ 1997;8:10111.[Abstract]
24 Zou CP, Kurie JM, Lotan D, Zou CC, Hong WK, Lotan R. Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 1998;4:134555.[Abstract]
25
Marchetti P, Zamzami N, Joseph B, Schraen-Maschke S, Mereau-Richard C, Costantini P, et al. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res 1999;59:625766.
26 Oridate N, Higuchi M, Suzuki S, Shroot B, Hong WK, Lotan R. Rapid induction of apoptosis in human C33A cervical carcinoma cells by the synthetic retinoid 6-[3-(1-adamantyl)hydroxyphenyl]-2-napthalene carboxylic acid (CD437). Int J Cancer 1997;70:4847.[Medline]
27 Aebi S, Kroning R, Cenni B, Sharma A, Fink D, Los G, et al. All-trans-retinoic acid enhances cisplatin-induced apoptosis in human ovarian and in squamous head and neck cancer cells. Clin Cancer Res 1997;3:20338.[Abstract]
28 Pastorino U, Warrell RP Jr, Formelli F. Clinical pharmacology of the retinoids. In: D. L. and P. D. R, editors. Retinoids in oncology. Berlin (Germany): Springer-Verlag; 1995. p. 5566.
29 Mariani L, Formelli F, De Palo G, Manzari A, Camerini T, Campa T, et al. Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerability. Tumori 1996,82;4449.[Medline]
30 Benbrook DM, Madler MM, Spruce LW, Birckbichler PJ, Nelson EC, Subramanian S, et al. Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity. J Med Chem 1997;40:356783.[Medline]
31 Zacheis D, Dhar A, Lu S, Madler MM, Klucik J, Brown CW, et al. Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors. J Med Chem 1999;42:443445.[Medline]
32
Dhar A, Liu S, Klucik J, Berlin KD, Madler MM, Lu S, et al. Synthesis, structureactivity relationships, and RAR-ligand interactions of nitrogen heteroarotinoids. J Med Chem 1999;42:360214.[Medline]
33 Benbrook DM, Subramanian S, Gale JB, Liu S, Brown CW, Boehm MF, et al. Synthesis and characterization of heteroarotinoids demonstrate structure specificity relationships. J Med Chem 1998;41:37537.[Medline]
34 Berlin KD, Benbrook DM, Nelson EC, Brown CW, Klucik J, Liu S. Heteroarotinoids contain urea or thiourea linker. Patent Pending; 2001.
35 Sondergaard G, Kaspersen P. Ovarian and extraovarian mucinous tumors with solid mural nodules. Int J Gynecol Pathol 1991;10:14555.[Medline]
36 Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:64151.[Abstract]
37
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1982;133:17105.
38 Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg A, Jakubowski A. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324:138593.[Abstract]
39 Baak JP, Wisse-Brekelmans EC, Langley FA, Talerman A, Delemarre JF. Morphometric data to FIGO stage and histological type and grade for prognosis of ovarian tumours. J Clin Pathol 1986;39:13406.[Abstract]
40 Tenti P, Aguzzi A, Riva C, Usellini L, Zappatore R, Bara J, et al. Ovarian mucinous tumors frequently express markers of gastric, intestinal, and pancreaticobiliary epithelial cells. Cancer 1992;69:213142.[Medline]
41 Yazawa S, Abbas SA, Madiyalakan R, Barlow JJ, Matta KL. N-Acetyl-beta-D-glucosaminyltransferases related to the synthesis of mucintype glycoproteins in human ovarian tissue. Carbohydr Res 1986;149:24152.[Medline]
42 Giuntoli RL, Rodriguez GC, Whitaker RS, Dodge R, Voynow JA. Mucin gene expression in ovarian cancers. Cancer Res 1998;58:554650.[Abstract]
43 Dong Y, Walsh MD, Cummings MC, Wright RG, Khoo SK, Parsons PG, et al. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J Pathol 1997;183:3117.[Medline]
44 Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 1980;605:3391.[Medline]
45 Guzman K, Gray TE, Yoon JH, Nettesheim P. Quantitation of mucin RNA by PCR reveals induction of both MUC2 and MUC5AC mRNA levels by retinoids. Am J Physiol 1996;271(6 Pt 1):10238.
46
Koo JS, Yoon JH, Gray T, Norford D, Jetten AM, Nettesheim P. Restoration of the mucous phenotype by retinoic acid in retinoid-deficient human bronchial cell cultures: changes in mucin gene expression. Am J Respir Cell Mol Biol 1999;20:4352.
47 Barratt-Boyes SM. Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol Immunother 1996;43:14251.[Medline]
48
Lloyd KO, Burchell J, Kudryashov V, Yin BW, Taylor-Papadimitriou J. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glyca chains in tumor cells. J Biol Chem 1996;271:3332534.
49 Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995;129:25565.[Abstract]
50 Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cellcell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996;7:56577.[Abstract]
51 Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC. The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 1996;56:42449.[Abstract]
52 Soprano DR, Chen LX, Wu S, Donigan AM, Borghaei RC, Soprano KJ. Overexpression of both RAR and RXR restores AP-1 repression in ovarian adenocarcinoma cells resistant to retinoic acid-dependent growth inhibition. Oncogene 1996;12:57784.[Medline]
53 Wu S, Donigan A, Platsoucas CD, Jung W, Soprano DR, Soprano KJ. All-trans-retinoic acid blocks cell cycle progression of human ovarian adenocarcinoma cells at late G1. Exp Cell Res 1997;232:27786.[Medline]
Manuscript received August 29, 2000; revised January 8, 2001; accepted January 25, 2001.
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |